Document is current

Article History

Received: 2 September 2022

Accepted: 20 December 2022

First Online: 7 January 2023

Declarations

:

: All methods were carried out in accordance with relevant guidelines and regulations. Ethical approval was obtained from West of Scotland Research Ethics Committee (18/WS/0035). The study was co-sponsored by University of Dundee and Tayside Health Board (2016CO01). Caldicott Guardian approval was received for data access (IGTCAL4762). Informed consent was not sought at the individual level due to the nature of the study; this was approved by the West of Scotland Research Ethics Committee (18/WS/0035).

: Not applicable.

: ER has no disclosures. JC has no disclosures. CJB has no disclosures. AR reports he has received research grants from Gilead, Bristol Myers Squibb, Abbvie and Roche and has received honorariums from Gilead and personal fees from Abbvie. LJB reports grants from NIHR during the conduct of the study. SKI has no disclosures. JT has served as a speaker, a consultant and an advisory board member for Abbvie, Bristol Myers Squibb, Gilead, Janssen, Merck Roche Sharp and Dohme and Roche. IM ER has no disclosures. DG ER has no disclosures. SJH reports honoraria from Gilead, unrelated to submitted work. MH has received unrestricted travel expenses and speaker fees for attending conferences and specialist meetings in last 5 years from Gilead and MSD. JFD declares research grants from AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck Sharpe and Dohme and Roche and other research grants and honoraria for lectures form AbbVie, Abbott, Bristol-Myers Squibb, Gilead, Janssen, Merck Sharpe and Dohme and Roche, outside the submitted work.